Arrowhead Pharmaceuticals
Clinical trials sponsored by Arrowhead Pharmaceuticals, explained in plain language.
Arrowhead Pharmaceuticals
ARWR
NASDAQ
Develops RNAi-based therapies for various diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame stubborn high cholesterol Results expected Sep 2026 (estimated)
- New drug aims to tackle rare brain disease Results expected Dec 2026 (estimated)
- New RNA injection targets obesity and diabetes in early trial Results expected Feb 2027 (estimated)
- New injection aims to tackle Alzheimer's at its roots Results expected Jun 2027 (estimated)
- New shot aims to slash sky-high cholesterol in rare genetic disease Results expected Aug 2027 (estimated)